What is claimed is:

1. Dihydropyrimidine derivatives of the following general formula (1), tautomers thereof and pharmaceutically acceptable salts thereof.




(1)

wherein Z represents a group of the following general formula (Z1) or (Z2), which is bonded to the nitrogen atom at a symbol "*".

(Z1)




(Z2)




wherein $B_1$ represents hydrogen atom, a lower alkyl group which may contain a hetero atom in the chain thereof, a lower alkylcarbonyl group (only when L represents oxygen atom, Y represents an interatomic bond and E represents hydrogen atom), an aryl-lower alkyl group, a

heteroaryl-lower alkyl group, a hydroxy-lower alkyl group, a halogeno-lower alkyl group, an amino-lower alkyl group, a carboxy-lower alkyl group, a lower alkyloxycarbonyl-lower alkyl group or a group of the following general formula (3) or (4):

(3) (4)


wherein $R^6$ to $R^8$ each represent hydrogen atom, a linear, branched or cyclic, saturated or unsaturated hydrocarbon group having 1 to 6 carbon atoms, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a hydroxy-lower alkyl group, a hydroxy-lower alkenyl group, a halogeno-lower alkyl group, a halogeno-lower alkenyl group, an amino-lower alkyl group, an amino-lower alkenyl group, a carboxy-lower alkyl group, a carboxy-lower alkenyl group, a substituted or unsubstituted aryl-lower alkyl group, a substituted or unsubstituted aryl-lower alkenyl group, a substituted or unsubstituted diaryl-lower alkyl group, a substituted or unsubstituted heteroaryl-lower alkyl group, a substituted or unsubstituted heteroaryl-lower alkenyl group, a cyano-lower alkyl group or a cyano-lower alkenyl group, and the chains of $R^6$ to $R^8$ may contain a hetero atom, with the proviso that when $R^6$ to $R^8$ each represent a linear, branched or cyclic, saturated or unsaturated hydrocarbon group having 1 to 6 carbon atoms, a substituted or unsubstituted aryl group, a hydroxy-lower alkyl group, a hydroxy-lower

alkenyl group, a halogeno-lower alkyl group, a halogeno-lower alkenyl group, a carboxy-lower alkyl group, a carboxy-lower alkenyl group, a substituted or unsubstituted aryl-lower alkyl group, a substituted or unsubstituted aryl-lower alkenyl group, a substituted or unsubstituted heteroaryl-lower alkyl group or, a substituted or unsubstituted heteroaryl-lower alkenyl group, L must be oxygen atom, Y must be an interatomic bond and E must be hydrogen atom,

$B_2$ represents an amino group, a lower alkyl group which may contain a hetero atom in the chain thereof, a lower alkylamino group, a lower alkylthio group, an aryl-lower alkyl group, a heteroaryl-lower alkyl group, a hydroxy-lower alkyl group, a halogeno-lower alkyl group, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group,

$X_2$ represents oxygen atom or sulfur atom,

A represents a group of the following general formula (2), or 1-naphthyl, 2-naphthyl, indole-2-yl, indole-3-yl, thiophene-3-yl, thiophene-2-yl, furan-3-yl, furan-2-yl, pyridine-4-yl, pyridine-3-yl or pyridine-2-yl group:

(2)




wherein $R^1$, $R^2$, $R^3$, $R^4$ and $R^5$ may be the same or different from each other and each represent hydrogen atom, a halogen atom, hydroxyl group, carboxyl group, amino group, cyano group, nitro group, a lower alkyl group, a lower alkoxyl group, a lower alkylamino group, a lower alkylthio

group, a lower alkanoyl group, a lower alkoxycarbonyl group, a hydroxy-lower alkyl group, a hydroxy-lower alkoxyl group, a hydroxy-lower alkenyl group, a halogeno-lower alkyl group, a halogeno-lower alkoxyl group, an amino-lower alkyl group, an amino-lower alkoxyl group, an amino-lower alkenyl group, a carboxy-lower alkyl group, a carboxy-lower alkoxyl group, a carboxy-lower alkenyl group, an aryl-lower alkoxyl group or an aroyl group,

C represents hydrogen atom, a lower alkyl group, a hydroxy-lower alkyl group, an aryl-lower alkyl group, a heteroaryl-lower alkyl group, an amino-lower alkyl group or a carboxy-lower alkyl group,

D represents hydrogen atom, a lower alkyl group, dimethoxymethyl group, cyano group, an aryl-lower alkyl group, a heteroaryl-lower alkyl group, a hydroxy-lower alkyl group, a halogeno-lower alkyl group, an amino-lower alkyl group, a carboxy-lower alkyl group or a group of the following general formula (5) or (6):

(5)



(6)



wherein $X_3$ represents O, S or N-$R_8$', n represents an integer of 0 to 6, K in general formula (5) represents hydrogen atom, a halogen atom, hydroxyl group, carboxyl group, amino group, cyano group, nitro group, azido group, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group, G in the general formula (6) represents N

or C-H, wherein $R^{8'}$ to $R^{10}$ may be the same or different from each other, and they each represent hydrogen atom, a linear, branched or cyclic, saturated or unsaturated hydrocarbon group having 1 to 6 carbon atoms, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a hydroxy-lower alkyl group, a hydroxy-lower alkenyl group, a halogeno-lower alkyl group, a halogeno-lower alkenyl group, an amino-lower alkyl group, an amino-lower alkenyl group, a carboxy-lower alkyl group, a carboxy-lower alkenyl group, an aryl-lower alkyl group, an aryl-lower alkenyl group, a heteroaryl-lower alkyl group, a heteroaryl-lower alkenyl group, a cyano-lower alkyl group or a cyano-lower alkenyl group, and the chains may contain a hetero atom, or $R^9$ and $R^{10}$ may together form a ring which may contain a hetero atom,

E represents hydrogen atom (only when L represents oxygen atom and Y represents an interatomic bond), a group of the following general formula (7), a substituted or unsubstituted heteroaryl group, cyclopentyl group, cyclohexyl group, pyrrolidinone-1-yl group or piperidinone-1-yl group:

(7)




wherein $R^{11}$, $R^{12}$, $R^{13}$, $R^{14}$ and $R^{15}$ may be the same or different from each other and each represent hydrogen atom, a halogen atom, hydroxyl group, carboxyl group, amino group, cyano group, nitro group, a lower alkyl

group, a lower alkoxyl group, a lower alkylamino group, a lower alkylthio group, a lower alkanoyl group, a hydroxy-lower alkyl group, a hydroxy-lower alkoxyl group, a hydroxy-lower alkenyl group, a halogeno-lower alkyl group, a halogeno-lower alkoxyl group, an amino-lower alkyl group, an amino-lower alkoxyl group, an amino-lower alkenyl group, a carboxy-lower alkyl group, a carboxy-lower alkoxyl group, a carboxy-lower alkenyl group, an aryl-lower alkyl group, an aryl-lower alkoxyl group, a lower alkoxycarbonyl group, an aroyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group or a saturated cyclic hydrocarbon having 3 to 8 carbon atoms, which may contain a hetero atom in the chain thereof and/or in the ring thereof,

$X_1$ represents an interatomic bond, $-CH_2-$, $-CH_2CH_2-$, $-CH=CH-$ or $-C\equiv C-$,

L represents >N-F or oxygen atom (only when Z represents $Z_1$),

wherein F represents hydrogen atom or a lower alkyl group which may contain a hetero atom in the chain thereof, a hydroxy-lower alkyl group, an amino-lower alkyl group, a carboxy-lower alkyl group or a lower alkyloxycarbonyl-lower alkyl group,

Y represents an interatomic bond (only when L represents oxygen atom and E represents hydrogen atom), a saturated or unsaturated linear hydrocarbon group having 1 to 6 carbon atoms, which may contain a hetero atom in the group thereof, or a group of the following general formula (8):

(8) 

wherein $R_{16}$ represents hydrogen atom, a substituted or unsubstituted, saturated or unsaturated linear, branched or cyclic hydrocarbon group having 1 to 6 carbon atoms, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a hydroxy-lower alkyl group, a hydroxy-lower alkenyl group, a halogeno-lower alkyl group, a halogeno-lower alkenyl group, an amino-lower alkyl group, an amino-lower alkenyl group, a carboxy-lower alkyl group, a carboxy-lower alkenyl group, an aryl-lower alkyl group, an aryl-lower alkenyl group, a heteroaryl-lower alkyl group, a heteroaryl-lower alkenyl group, a cyano-lower alkyl group or a cyano-lower alkenyl group, and the chains of $R^{16}$ may contain a hetero atom, and m represents an integer of 0 to 5.

2. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_1$ and L represents >N-F.

3. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_1$, L represents >N-F, A represents a group of general formula (2), $B_1$ represents hydrogen atom and $X_1$ represents an interatomic bond.

4. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_1$, L represents >N-F, A represents a group of general formula (2), $B_1$ represents hydrogen atom, E represents a group of general formula

(7), thiophene-3-yl group, thiophene-2-yl group, furan-3-yl group, furan-2-yl group, pyridine-4-yl group, pyridine-3-yl group, pyridine-2-yl group or imidazole-1-yl group and $X_1$ represents an interatomic bond.

5. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_1$, L represents >N-F, A represents a group of general formula (2), $B_1$, C and F each represent hydrogen atom, E represents a group of general formula (7) and $X_1$ represents an interatomic bond.

6. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_1$, L represents >N-F, A represents a group of general formula (2), $B_1$, C and F each represent hydrogen atom, D represents a lower alkyl group, E represents a group of general formula (7), $X_1$ represents an interatomic bond and Y represents a group of general formula (8) wherein m represents an integer of 1 to 4 and $R_{16}$ represents a substituted or unsubstituted aryl group.

7. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_1$, L represents >N-F, A represents a group of general formula (2), $B_1$, C and F each represent hydrogen atom, D represents a lower alkyl group, E represents a group of general formula (7) and $X_1$ represents an interatomic bond.

8. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_1$, L represents >N-F, A represents a group of general formula (2), $B_1$, C and F each represent hydrogen atom, D represents a group of

general formula (5) wherein $X_3$ represents oxygen atom and n represents an integer of 1 to 3, E represents a group of general formula (7) and $X_1$ represents an interatomic bond.

9. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_1$, L represents >N-F, A represents a group of general formula (2), $B_1$, C and F each represent hydrogen atom, D represents a group of general formula (6) wherein $X_3$ represents oxygen atom and n represents an integer of 1 to 3, E represents a group of general formula (7) and $X_1$ represents an interatomic bond.

10. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_1$, L represents >N-F, A represents a group of general formula (2), C and F each represent hydrogen atom, $B_1$ represents a group of general formula (4), $R_7$ and $R_8$ each represent hydrogen atom, $X_1$ represents an interatomic bond and $X_2$ represents an oxygen atom.

11. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_1$, L represents >N-F, A represents a group of general formula (2), $B_1$, C and F each represent hydrogen atom, D represents a lower alkyl group, E represents a group of general formula (7), $X_1$ represents an interatomic bond and Y represents a group of general formula (8), wherein m represents an integer of 1 to 4 and $R_{16}$ represents a substituted or unsubstituted aryl group, or a saturated or unsaturated hydrocarbon group having 3 or 4 carbon atoms.

12. An N-type calcium channel antagonist comprising a

dihydropyrimidine derivative, a tautomer thereof or a pharmaceutically acceptable salt thereof according to any of claims 1 to 11 as an active ingredient.

13. A therapeutic agent comprising a dihydropyrimidine derivative, a tautomer thereof or a pharmaceutically acceptable salt thereof according to any of claims 1 to 11 as the active ingredient, for any of acute stage of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, pain caused by thromboangiitis obliterans, postoperative pain, migraine, visceral pain, bronchial asthma, unstable angina, irritable colitis and withdrawal symptoms after addiction to drugs.

14. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_2$, L represents >N-F and C represents hydrogen atom.

15. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_2$, L represents >N-F, C represents hydrogen atom, A represents a group of general formula (2), F represents hydrogen atom and $X_1$ represents an interatomic bond.

16. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_2$, L represents >N-F, C represents hydrogen atom, A represents a group of general formula (2), E represents a group of general formula (7), F represents hydrogen atom and $X_1$ represents an interatomic

bond.

17. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_2$, L represents >N-F, C represents hydrogen atom, A represents a group of general formula (2), E represents a group of general formula (7), F represents hydrogen atom, $X_1$ represents an interatomic bond and $B_2$ represents a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group.

18. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_2$, L represents >N-F, C represents hydrogen atom, A represents a group of general formula (2), D represents a group of general formula (6) wherein $X_3$ represents oxygen atom and n represents an integer of 2 or 3, E represents a group of general formula (7), F represents hydrogen atom and $X_1$ represents an interatomic bond.

19. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_2$, L represents >N-F, C represents hydrogen atom, A represents a group of general formula (2), E represents a group of general formula (7), F represents hydrogen atom, $X_1$ represents an interatomic bond and Y represents a group of general formula (8), wherein m represents an integer of 1 to 4 and $R_{16}$ represents a substituted or unsubstituted aryl group.

20. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_2$, L represents >N-F, C represents hydrogen atom, A

represents a group of general formula (2), E represents a group of general formula (7), F represents hydrogen atom, $X_1$ represents an interatomic bond and Y represents an unsaturated hydrocarbon group having 3 or 4 carbon atoms.

21. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_2$, L represents >N-F, C represents hydrogen atom, A represents a group of general formula (2), D represents a group of general formula (6), wherein $X_3$ represents oxygen atom, n represents an integer of 2 or 3 and $R_9$ and $R_{10}$, bonded together to form a 5- to 7-membered ring together with G, E represents a group of general formula (7), F represents hydrogen atom, $X_1$ represents an interatomic bond and Y represents a group of general formula (8), wherein m represents an integer of 1 to 4 and $R_{16}$ represents a substituted or unsubstituted aryl group, or an unsaturated hydrocarbon group having 3 or 4 carbon atoms.

22. Dihydropyrimidine derivatives which are following compounds (9) and (10), tautomers thereof and pharmaceutically acceptable salts thereof:

4-(3-chlorophenyl)-6-[(2-cyclohexylethoxy)methyl]-5-(3,3-diphenylpropyl-carbamoyl)-2-phenyl-1,4-dihydropyrimidine [compound (9)], and

4-(3-chlorophenyl)-6-[(2-cyclohexylethoxy)methyl]-2-phenyl-5-[(3-phenyl-2-propene-1-yl)carbamoyl]-1,4-dihydropyrimidine [compound (10)]:

(9) 

(10) 

23. An N-type calcium channel antagonist comprising a dihydropyrimidine derivative, a tautomer thereof or a pharmaceutically acceptable salt thereof according to any of claims 14 to 22 as an active ingredient.

24. A therapeutic agent comprising a dihydropyrimidine derivative or a pharmaceutically acceptable salt thereof according to any of claims 14 to 22 as the active ingredient, for any of acute stage of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, pain caused by thromboangiitis obliterans, postoperative pain, migraine, visceral pain, bronchial asthma, unstable angina, irritable colitis and withdrawal symptoms after addiction to drugs.

25. A pharmaceutical composition comprising a dihydropyrimidine derivative, a tautomer thereof or a pharmaceutically acceptable salt thereof according to any of claims 1 to 11 or claims 14 to 22 as an active ingredient.

26. The dihydropyrimidine derivatives, tautomers thereof and pharmaceutically acceptable salts thereof according to claim 1, wherein Z represents $Z_1$, L represents oxygen atom, Y represents an interatomic bond, E represents hydrogen atom, A represents a group of general formula (2), $B_1$ represents a group of general formula (4), $X_1$ represents an interatomic bond and $X_2$ represents oxygen atom.

27. An N-type calcium channel antagonist comprising a dihydropyrimidine derivative, a tautomer thereof or a pharmaceutically acceptable salt thereof according to claim 26 as an active ingredient.

28. A therapeutic agent comprising a dihydropyrimidine derivative or a pharmaceutically acceptable salt thereof according to claim 26 as the active ingredient, for any of acute stage of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, pain caused by thromboangiitis obliterans, postoperative pain, migraine, visceral pain, bronchial asthma, unstable angina, irritable colitis and withdrawal symptoms after addiction to drugs.

29. An N-type calcium channel antagonist comprising a dihydropyrimidine derivative of the following general formula (1), a tautomer thereof or a pharmaceutically acceptable salt thereof as the active ingredient:




(1)

wherein Z represents a group of the following general formula (Z1) or (Z2), which is bonded to the nitrogen atom at a symbol "*".

(Z1)




(Z2)




wherein $B_1$ represents hydrogen atom, a lower alkyl group which may contain a hetero atom in the chain thereof, a lower alkylcarbonyl group, an aryl-lower alkyl group, a heteroaryl-lower alkyl group, a hydroxy-lower alkyl group, a halogeno-lower alkyl group, an amino-lower alkyl group, a carboxy-lower alkyl group, a lower alkyloxycarbonyl-lower alkyl group or a group of the following general formula (3) or (4):

(3) (4)







wherein $R^6$ to $R^8$ each represent hydrogen atom, a linear, branched or cyclic, saturated or unsaturated hydrocarbon group having 1 to 6 carbon atoms, an alkyl group substituted with a cyclic alkyl group which may contain a hetero atom, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a hydroxy-lower alkyl group, a hydroxy-lower alkenyl group, a halogeno-lower alkyl group, a halogeno-lower alkenyl group, an amino-lower alkyl group, an amino-lower alkenyl group, a carboxy-lower alkyl group, a carboxy-lower alkenyl group, a substituted or unsubstituted aryl-lower alkyl group, a substituted or unsubstituted aryl-lower alkenyl group, a substituted or unsubstituted diaryl-lower alkyl group, a substituted or unsubstituted heteroaryl-lower alkyl group, a substituted or unsubstituted heteroaryl-lower alkenyl group, a cyano-lower alkyl group or a cyano-lower alkenyl group, and the chains of $R^6$ to $R^8$ may contain a hetero atom, or $R^7$ and $R^8$ may together form a ring which may contain a hetero atom,

$B_2$ represents an amino group, a lower alkyl group which may contain a hetero atom in the chain thereof, a lower alkylamino group, a lower alkylthio group, an aryl-lower alkyl group, a heteroaryl-lower alkyl group, a hydroxy-lower alkyl group, a halogeno-lower alkyl group, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group,

$X_2$ represents oxygen atom or sulfur atom,

A represents a group of the following general formula (2), or l-naphthyl, 2-naphthyl, indole-2-yl, indole-3-yl, thiophene-3-yl, thiophene-2-yl, furan-3-yl, furan-2-yl, pyridine-4-yl, pyridine-3-yl or pyridine-2-yl group:

(2)




wherein $R^1$, $R^2$, $R^3$, $R^4$ and $R^5$ may be the same or different from each other and each represent hydrogen atom, a halogen atom, hydroxyl group, carboxyl group, amino group, cyano group, nitro group, a lower alkyl group, a lower alkoxyl group, a lower alkylamino group, a lower alkylthio group, a lower alkanoyl group, a lower alkoxycarbonyl group, a hydroxy-lower alkyl group, a hydroxy-lower alkoxyl group, a hydroxy-lower alkenyl group, a halogeno-lower alkyl group, a halogeno-lower alkoxyl group, an amino-lower alkyl group, an amino-lower alkoxyl group, an amino-lower alkenyl group, a carboxy-lower alkyl group, a carboxy-lower alkoxyl group, a carboxy-lower alkenyl group, an aryl-lower alkoxyl group or an aroyl group,

C represents hydrogen atom, a lower alkyl group, a hydroxy-lower alkyl group, an aryl-lower alkyl group, a heteroaryl-lower alkyl group, an amino-lower alkyl group or a carboxy-lower alkyl group,

D represents hydrogen atom, a lower alkyl group, dimethoxymethyl group, cyano group, an aryl-lower alkyl group, a heteroaryl-lower alkyl group, a hydroxy-lower alkyl group, a halogeno-lower alkyl group, an amino-lower alkyl group, a carboxy-lower alkyl group or a group of the following

general formula (5) or (6):

(5)



(6)



wherein $X_3$ represents O, S or N-$R_8$', n represents an integer of 0 to 6, K in general formula (5) represents hydrogen atom, a halogen atom, hydroxyl group, carboxyl group, amino group, cyano group, nitro group, azido group, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group, G in the general formula (6) represents N or C-H, wherein $R^{8'}$ to $R^{10}$ may be the same or different from each other, and they each represent hydrogen atom, a linear, branched or cyclic, saturated or unsaturated hydrocarbon group having 1 to 6 carbon atoms, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a hydroxy-lower alkyl group, a hydroxy-lower alkenyl group, a halogeno-lower alkyl group, a halogeno-lower alkenyl group, an amino-lower alkyl group, an amino-lower alkenyl group, a carboxy-lower alkyl group, a carboxy-lower alkenyl group, an aryl-lower alkyl group, an aryl-lower alkenyl group, a heteroaryl-lower alkyl group, a heteroaryl-lower alkenyl group, a cyano-lower alkyl group or a cyano-lower alkenyl group, and the chains may contain a hetero atom, or $R^9$ and $R^{10}$ may together form a ring which may contain a hetero atom,

E represents hydrogen atom (only when L represents oxygen atom and Y represents an interatomic bond), a group of the following general formula

(7), a substituted or unsubstituted heteroaryl group, cyclopentyl group, cyclohexyl group, morpholine-1-yl group, pyrrolidine-1-yl group, pyrrolidinone-1-yl group, piperidine-1-yl group, piperidinone-1-yl group, piperazine-1-yl group, homopiperidine-1-yl group or homopiprazine-1-yl group:

(7)




wherein $R^{11}$, $R^{12}$, $R^{13}$, $R^{14}$ and $R^{15}$ may be the same or different from each other and each represent hydrogen atom, a halogen atom, hydroxyl group, carboxyl group, amino group, cyano group, nitro group, a lower alkyl group, a lower alkoxyl group, a lower alkylamino group, a lower alkylthio group, a lower alkanoyl group, a hydroxy-lower alkyl group, a hydroxy-lower alkoxyl group, a hydroxy-lower alkenyl group, a halogeno-lower alkyl group, a halogeno-lower alkoxyl group, an amino-lower alkyl group, an amino-lower alkoxyl group, an amino-lower alkenyl group, a carboxy-lower alkyl group, a carboxy-lower alkoxyl group, a carboxy-lower alkenyl group, an aryl-lower alkyl group, an aryl-lower alkoxyl group, a lower alkoxycarbonyl group, an aroyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group or a saturated cyclic hydrocarbon group having 3 to 8 carbon atoms, which may contain a hetero atom in the chain thereof and/or in the ring thereof,

$X_1$ represents an interatomic bond, $-CH_2-$, $-CH_2CH_2-$, $-CH=CH-$ or $-C\equiv C-$,

L represents >N-F or oxygen atom (only when Z represents $Z_1$) wherein F

represents hydrogen atom or a lower alkyl group which may contain a hetero atom in the chain thereof, a hydroxy-lower alkyl group, an amino-lower alkyl group, a carboxy-lower alkyl group or a lower alkyloxycarbonyl-lower alkyl group,

Y represents an interatomic bond (only when L represents oxygen atom and E represents hydrogen atom), a saturated or unsaturated linear hydrocarbon group having 1 to 6 carbon atoms, which may contain a hetero atom in the group thereof, or a group of the following general formula (8):

(8)




wherein $R_{16}$ represents hydrogen atom, a substituted or unsubstituted, saturated or unsaturated linear, branched or cyclic hydrocarbon group having 1 to 6 carbon atoms, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a hydroxy-lower alkyl group, a hydroxy-lower alkenyl group, a halogeno-lower alkyl group, a halogeno-lower alkenyl group, an amino-lower alkyl group, an amino-lower alkenyl group, a carboxy-lower alkyl group, a carboxy-lower alkenyl group, an aryl-lower alkyl group, an aryl-lower alkenyl group, a heteroaryl-lower alkyl group, a heteroaryl-lower alkenyl group, a cyano-lower alkyl group or a cyano-lower alkenyl group, and the chains of $R^{16}$ may contain a hetero atom, and m represents an integer of 0 to 5.

30. A therapeutic agent comprising a dihydropyrimidine derivative or a pharmaceutically acceptable salt thereof according to claim 29 as the

active ingredient, for any of acute stage of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease, progressive neurodegenerative diseases, neuropathy caused by head injury, pain caused by thromboangiitis obliterans, postoperative pain, migraine, visceral pain, bronchial asthma, unstable angina, irritable colitis and withdrawal symptoms after addiction to drugs.